ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...
Clinical Trials Arena on MSN
Novocure’s Optune Gio fails to show benefit at earlier stage
The Phase III TRIDENT study failed to show statistical significance in OS when Optune Gio was used earlier.
The MarketWatch News Department was not involved in the creation of this content. Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 ...
By Sneha S K June 18 (Reuters) - Novocure said on Thursday that a late-stage trial showed early use of its non-invasive cancer therapy did not significantly improve overall survival in patients with ...
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for ...
NVCR wins Japan National Health Insurance reimbursement for Optune Lua in NSCLC patients. Coverage in Japan could expand patient access and drive adoption of Novocure's TTFields therapy platform. NVCR ...
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances ...
Novocure secured FDA approval for Optune Pax with gem/nab-pac in locally advanced pancreatic cancer. Phase III PANOVA-3 showed median OS of 16.2 months vs 14.2 with gem/nab-pac alone. Optune Pax ...
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on ...
Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results